A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Micro-Abstract A phase II randomized study of pemetrexed combined with cisplatin or carboplatin as first-line treatment for stage IIIB/IV non–small-cell lung cancer. Sixty-five patients were randomized to each arm. The results of the 6-month progression-free survival rate, median overall survival, a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2013-05, Vol.14 (3), p.215-223
Main Authors: Schuette, Wolfgang H.W, Gröschel, Andreas, Sebastian, Martin, Andreas, Stefan, Müller, Thomas, Schneller, Folker, Guetz, Sylvia, Eschbach, Corinna, Bohnet, Sabine, Leschinger, Monika I, Reck, Martin
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carboplatin - adverse effects
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Cisplatin - administration & dosage
Cisplatin - adverse effects
Disease-Free Survival
Female
First-line treatment
Glutamates - administration & dosage
Glutamates - adverse effects
Guanine - administration & dosage
Guanine - adverse effects
Guanine - analogs & derivatives
Hematology, Oncology and Palliative Medicine
Humans
Kaplan-Meier Estimate
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Male
Middle Aged
Neoplasm Metastasis
Nonsquamous histology
Pemetrexed
Platinum combinations
Pulmonary/Respiratory
Stage IIIB/IV non–small-cell lung cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract A phase II randomized study of pemetrexed combined with cisplatin or carboplatin as first-line treatment for stage IIIB/IV non–small-cell lung cancer. Sixty-five patients were randomized to each arm. The results of the 6-month progression-free survival rate, median overall survival, and safety analyses demonstrated efficacy and tolerability of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with advanced non–small-cell lung cancer.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2012.10.001